CA2887096C - Benzamides inhibitors of the p2x7 receptor - Google Patents
Benzamides inhibitors of the p2x7 receptor Download PDFInfo
- Publication number
- CA2887096C CA2887096C CA2887096A CA2887096A CA2887096C CA 2887096 C CA2887096 C CA 2887096C CA 2887096 A CA2887096 A CA 2887096A CA 2887096 A CA2887096 A CA 2887096A CA 2887096 C CA2887096 C CA 2887096C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- benzamide
- trifluoromethyl
- chloro
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101710189965 P2X purinoceptor 7 Proteins 0.000 title abstract description 20
- 102100037602 P2X purinoceptor 7 Human genes 0.000 title abstract description 20
- 239000003112 inhibitor Substances 0.000 title description 3
- 229940054066 benzamide antipsychotics Drugs 0.000 title description 2
- 150000003936 benzamides Chemical class 0.000 title description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims abstract description 480
- 150000001875 compounds Chemical class 0.000 claims abstract description 290
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 139
- 150000003839 salts Chemical class 0.000 claims description 121
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 70
- -1 homomorpholinyl Chemical group 0.000 claims description 45
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 40
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 33
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 239000000460 chlorine Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 239000011737 fluorine Chemical group 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical group 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 8
- 208000004296 neuralgia Diseases 0.000 claims description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 7
- 125000002393 azetidinyl group Chemical group 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000002757 morpholinyl group Chemical group 0.000 claims description 7
- 208000021722 neuropathic pain Diseases 0.000 claims description 7
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- 125000003386 piperidinyl group Chemical group 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- LFVFUUBRPMCKGZ-UHFFFAOYSA-N 2,3-dichloro-n-[2-(4,4-difluorocyclohexyl)-2-(2-methylpyrimidin-5-yl)ethyl]benzamide Chemical compound C1=NC(C)=NC=C1C(C1CCC(F)(F)CC1)CNC(=O)C1=CC=CC(Cl)=C1Cl LFVFUUBRPMCKGZ-UHFFFAOYSA-N 0.000 claims description 4
- DLDVJLNENOLKMS-UHFFFAOYSA-N 2-chloro-n-[2-(4,4-difluorocyclohexyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-3-fluorobenzamide Chemical compound FC1=CC=CC(C(=O)NCC(C2CCC(F)(F)CC2)C=2C=NC(=NC=2)C(F)(F)F)=C1Cl DLDVJLNENOLKMS-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- KMYKPPPJRDAZAH-UHFFFAOYSA-N 2,3-dichloro-n-[2-(4,4-difluorocyclohexyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide Chemical compound C1=NC(C(F)(F)F)=NC=C1C(C1CCC(F)(F)CC1)CNC(=O)C1=CC=CC(Cl)=C1Cl KMYKPPPJRDAZAH-UHFFFAOYSA-N 0.000 claims description 3
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 3
- SILHYWNUBWSHLP-UHFFFAOYSA-N 2,3-dichloro-n-[4-methoxy-2-[2-(trifluoromethyl)pyrimidin-5-yl]butyl]benzamide Chemical compound C=1N=C(C(F)(F)F)N=CC=1C(CCOC)CNC(=O)C1=CC=CC(Cl)=C1Cl SILHYWNUBWSHLP-UHFFFAOYSA-N 0.000 claims description 2
- CZZCGJUWTKLBJN-UHFFFAOYSA-N 2,3-dichloro-n-[[4,4-difluoro-1-(2-methylpyrimidin-5-yl)cyclohexyl]methyl]benzamide Chemical compound C1=NC(C)=NC=C1C1(CNC(=O)C=2C(=C(Cl)C=CC=2)Cl)CCC(F)(F)CC1 CZZCGJUWTKLBJN-UHFFFAOYSA-N 0.000 claims description 2
- XVRIONFSORODKW-UHFFFAOYSA-N 2,3-dichloro-n-[[4-[2-(trifluoromethyl)pyrimidin-5-yl]oxan-4-yl]methyl]benzamide Chemical compound C1=NC(C(F)(F)F)=NC=C1C1(CNC(=O)C=2C(=C(Cl)C=CC=2)Cl)CCOCC1 XVRIONFSORODKW-UHFFFAOYSA-N 0.000 claims description 2
- QSLKTTDGZTXERS-UHFFFAOYSA-N 2-chloro-n-[2-(4,4-difluorocyclohexyl)-2-(2-methylpyrimidin-5-yl)ethyl]-3-fluorobenzamide Chemical compound C1=NC(C)=NC=C1C(C1CCC(F)(F)CC1)CNC(=O)C1=CC=CC(F)=C1Cl QSLKTTDGZTXERS-UHFFFAOYSA-N 0.000 claims description 2
- HOJQVRLDJWLPMZ-UHFFFAOYSA-N 2-chloro-n-[2-(4,4-difluorocyclohexyl)-2-(2-methylpyrimidin-5-yl)ethyl]-6-fluorobenzamide Chemical compound C1=NC(C)=NC=C1C(C1CCC(F)(F)CC1)CNC(=O)C1=C(F)C=CC=C1Cl HOJQVRLDJWLPMZ-UHFFFAOYSA-N 0.000 claims description 2
- GXEMBQFZPKJEEH-UHFFFAOYSA-N 2-chloro-n-[[4-[2-(trifluoromethyl)pyrimidin-5-yl]oxan-4-yl]methyl]benzamide Chemical compound C1=NC(C(F)(F)F)=NC=C1C1(CNC(=O)C=2C(=CC=CC=2)Cl)CCOCC1 GXEMBQFZPKJEEH-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- HNVTXPSBGUAYNT-UHFFFAOYSA-N 2,3-dichloro-n-[3-cyclopropyl-2-(2-methylpyrimidin-5-yl)propyl]benzamide Chemical compound C1=NC(C)=NC=C1C(CC1CC1)CNC(=O)C1=CC=CC(Cl)=C1Cl HNVTXPSBGUAYNT-UHFFFAOYSA-N 0.000 claims 3
- FUNGXBHNVRVIFC-UHFFFAOYSA-N 2,6-dichloro-n-[3-cyclopropyl-2-[2-(trifluoromethyl)pyrimidin-5-yl]propyl]benzamide Chemical compound C1=NC(C(F)(F)F)=NC=C1C(CC1CC1)CNC(=O)C1=C(Cl)C=CC=C1Cl FUNGXBHNVRVIFC-UHFFFAOYSA-N 0.000 claims 3
- CYWXHUBBXYVEIN-UHFFFAOYSA-N 2-chloro-n-[3-cyclopropyl-2-[2-(trifluoromethyl)pyrimidin-5-yl]propyl]benzamide Chemical compound C1=NC(C(F)(F)F)=NC=C1C(CC1CC1)CNC(=O)C1=CC=CC=C1Cl CYWXHUBBXYVEIN-UHFFFAOYSA-N 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- YUCWDLRQIHDFJE-UHFFFAOYSA-N 2,3-dichloro-n-[2-(2-methylpyrimidin-5-yl)-2-(oxan-4-yl)ethyl]benzamide Chemical compound C1=NC(C)=NC=C1C(C1CCOCC1)CNC(=O)C1=CC=CC(Cl)=C1Cl YUCWDLRQIHDFJE-UHFFFAOYSA-N 0.000 claims 2
- SVXAGFVIOFXJNP-UHFFFAOYSA-N 2,3-dichloro-n-[2-(2-methylpyrimidin-5-yl)-3-[1-(trifluoromethyl)cyclopropyl]propyl]benzamide Chemical compound C1=NC(C)=NC=C1C(CC1(CC1)C(F)(F)F)CNC(=O)C1=CC=CC(Cl)=C1Cl SVXAGFVIOFXJNP-UHFFFAOYSA-N 0.000 claims 2
- IGFZEMQKBHZFBX-UHFFFAOYSA-N 2,3-dichloro-n-[2-(4-fluorophenyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide Chemical compound C1=CC(F)=CC=C1C(C=1C=NC(=NC=1)C(F)(F)F)CNC(=O)C1=CC=CC(Cl)=C1Cl IGFZEMQKBHZFBX-UHFFFAOYSA-N 0.000 claims 2
- VGRRYOMBWKYPIG-UHFFFAOYSA-N 2,3-dichloro-n-[2-(oxan-4-yl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide Chemical compound C1=NC(C(F)(F)F)=NC=C1C(C1CCOCC1)CNC(=O)C1=CC=CC(Cl)=C1Cl VGRRYOMBWKYPIG-UHFFFAOYSA-N 0.000 claims 2
- GAXAVEJOQGMPBF-UHFFFAOYSA-N 2,3-dichloro-n-[3-[1-(trifluoromethyl)cyclopropyl]-2-[2-(trifluoromethyl)pyrimidin-5-yl]propyl]benzamide Chemical compound C1=NC(C(F)(F)F)=NC=C1C(CC1(CC1)C(F)(F)F)CNC(=O)C1=CC=CC(Cl)=C1Cl GAXAVEJOQGMPBF-UHFFFAOYSA-N 0.000 claims 2
- WYMCMIODUHKIJX-UHFFFAOYSA-N 2,6-dichloro-n-[3-cyclopropyl-2-(2-methylpyrimidin-5-yl)propyl]benzamide Chemical compound C1=NC(C)=NC=C1C(CC1CC1)CNC(=O)C1=C(Cl)C=CC=C1Cl WYMCMIODUHKIJX-UHFFFAOYSA-N 0.000 claims 2
- DBHQTGWJHCEZNO-UHFFFAOYSA-N 2-chloro-3-fluoro-n-[2-(oxan-4-yl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide Chemical compound FC1=CC=CC(C(=O)NCC(C2CCOCC2)C=2C=NC(=NC=2)C(F)(F)F)=C1Cl DBHQTGWJHCEZNO-UHFFFAOYSA-N 0.000 claims 2
- QWYFYNINCUEIPS-UHFFFAOYSA-N 2-chloro-3-fluoro-n-[3-[1-(trifluoromethyl)cyclopropyl]-2-[2-(trifluoromethyl)pyrimidin-5-yl]propyl]benzamide Chemical compound FC1=CC=CC(C(=O)NCC(CC2(CC2)C(F)(F)F)C=2C=NC(=NC=2)C(F)(F)F)=C1Cl QWYFYNINCUEIPS-UHFFFAOYSA-N 0.000 claims 2
- YADAFFKKFONQQM-UHFFFAOYSA-N 2-chloro-6-fluoro-n-[2-(4-fluorophenyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide Chemical compound C1=CC(F)=CC=C1C(C=1C=NC(=NC=1)C(F)(F)F)CNC(=O)C1=C(F)C=CC=C1Cl YADAFFKKFONQQM-UHFFFAOYSA-N 0.000 claims 2
- NEIYKUQZCAIFPQ-UHFFFAOYSA-N 2-chloro-6-fluoro-n-[2-(oxan-4-yl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide Chemical compound FC1=CC=CC(Cl)=C1C(=O)NCC(C=1C=NC(=NC=1)C(F)(F)F)C1CCOCC1 NEIYKUQZCAIFPQ-UHFFFAOYSA-N 0.000 claims 2
- KTHYXVISZNVVNJ-UHFFFAOYSA-N 2-chloro-n-[2-(2-methylpyrimidin-5-yl)-2-(oxan-4-yl)ethyl]benzamide Chemical compound C1=NC(C)=NC=C1C(C1CCOCC1)CNC(=O)C1=CC=CC=C1Cl KTHYXVISZNVVNJ-UHFFFAOYSA-N 0.000 claims 2
- BBABFHCUJHALBA-UHFFFAOYSA-N 2-chloro-n-[2-(4,4-difluorocyclohexyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-6-fluorobenzamide Chemical compound FC1=CC=CC(Cl)=C1C(=O)NCC(C=1C=NC(=NC=1)C(F)(F)F)C1CCC(F)(F)CC1 BBABFHCUJHALBA-UHFFFAOYSA-N 0.000 claims 2
- AKKNTLAHCTWLLO-UHFFFAOYSA-N 2-chloro-n-[2-(4,4-difluorocyclohexyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide Chemical compound C1=NC(C(F)(F)F)=NC=C1C(C1CCC(F)(F)CC1)CNC(=O)C1=CC=CC=C1Cl AKKNTLAHCTWLLO-UHFFFAOYSA-N 0.000 claims 2
- QLQIKVJKFWIZSN-UHFFFAOYSA-N 2-chloro-n-[2-(4-fluorophenyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide Chemical compound C1=CC(F)=CC=C1C(C=1C=NC(=NC=1)C(F)(F)F)CNC(=O)C1=CC=CC=C1Cl QLQIKVJKFWIZSN-UHFFFAOYSA-N 0.000 claims 2
- KIOOGQHTHHNPEG-UHFFFAOYSA-N 2-chloro-n-[2-(oxan-4-yl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide Chemical compound C1=NC(C(F)(F)F)=NC=C1C(C1CCOCC1)CNC(=O)C1=CC=CC=C1Cl KIOOGQHTHHNPEG-UHFFFAOYSA-N 0.000 claims 2
- HJUJINBFFMFWOK-UHFFFAOYSA-N 2-chloro-n-[3-cyclopropyl-2-[2-(trifluoromethyl)pyrimidin-5-yl]propyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NCC(CC2CC2)C=2C=NC(=NC=2)C(F)(F)F)=C1Cl HJUJINBFFMFWOK-UHFFFAOYSA-N 0.000 claims 2
- VQMPIFDHXSJHBL-UHFFFAOYSA-N 2-chloro-n-[3-cyclopropyl-2-methyl-2-[2-(trifluoromethyl)pyrimidin-5-yl]propyl]-3-fluorobenzamide Chemical compound C1CC1CC(C=1C=NC(=NC=1)C(F)(F)F)(C)CNC(=O)C1=CC=CC(F)=C1Cl VQMPIFDHXSJHBL-UHFFFAOYSA-N 0.000 claims 2
- WJFDKOHMAALCBK-UHFFFAOYSA-N 2-chloro-n-[3-cyclopropyl-2-methyl-2-[2-(trifluoromethyl)pyrimidin-5-yl]propyl]benzamide Chemical compound C1CC1CC(C=1C=NC(=NC=1)C(F)(F)F)(C)CNC(=O)C1=CC=CC=C1Cl WJFDKOHMAALCBK-UHFFFAOYSA-N 0.000 claims 2
- GBLQZOHBPMHPDB-UHFFFAOYSA-N FC1=CC=CC(C(=O)NCC(CC2CC2)C=2C=NC(=NC=2)C(F)(F)F)=C1Cl Chemical compound FC1=CC=CC(C(=O)NCC(CC2CC2)C=2C=NC(=NC=2)C(F)(F)F)=C1Cl GBLQZOHBPMHPDB-UHFFFAOYSA-N 0.000 claims 2
- QMCVZDMPWUCYFJ-UHFFFAOYSA-N n-[3-cyclopropyl-2-[2-(trifluoromethyl)pyrimidin-5-yl]propyl]-3-methoxy-2-methylbenzamide Chemical compound COC1=CC=CC(C(=O)NCC(CC2CC2)C=2C=NC(=NC=2)C(F)(F)F)=C1C QMCVZDMPWUCYFJ-UHFFFAOYSA-N 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- BCABALOMZTTXRL-UHFFFAOYSA-N 2,3-dichloro-n-[2-(2-methylpyrimidin-5-yl)-2-pyridin-4-ylethyl]benzamide Chemical compound C1=NC(C)=NC=C1C(C=1C=CN=CC=1)CNC(=O)C1=CC=CC(Cl)=C1Cl BCABALOMZTTXRL-UHFFFAOYSA-N 0.000 claims 1
- RHDROFHJDUDMGT-UHFFFAOYSA-N 2,3-dichloro-n-[3-cyclopropyl-2-[2-(trifluoromethyl)pyrimidin-5-yl]propyl]benzamide Chemical compound C1=NC(C(F)(F)F)=NC=C1C(CC1CC1)CNC(=O)C1=CC=CC(Cl)=C1Cl RHDROFHJDUDMGT-UHFFFAOYSA-N 0.000 claims 1
- XTPKQBKANGHQJW-UHFFFAOYSA-N 2,3-dichloro-n-[3-cyclopropyl-2-methyl-2-[2-(trifluoromethyl)pyrimidin-5-yl]propyl]benzamide Chemical compound C1CC1CC(C=1C=NC(=NC=1)C(F)(F)F)(C)CNC(=O)C1=CC=CC(Cl)=C1Cl XTPKQBKANGHQJW-UHFFFAOYSA-N 0.000 claims 1
- UPZAMGNRGNYKDQ-UHFFFAOYSA-N 2,3-dichloro-n-[[3-(2-methylpyrimidin-5-yl)oxolan-3-yl]methyl]benzamide Chemical compound C1=NC(C)=NC=C1C1(CNC(=O)C=2C(=C(Cl)C=CC=2)Cl)COCC1 UPZAMGNRGNYKDQ-UHFFFAOYSA-N 0.000 claims 1
- YUZMKQKVLJEEJJ-UHFFFAOYSA-N 2,3-dichloro-n-[[4,4-difluoro-1-[2-(trifluoromethyl)pyrimidin-5-yl]cyclohexyl]methyl]benzamide Chemical compound C1=NC(C(F)(F)F)=NC=C1C1(CNC(=O)C=2C(=C(Cl)C=CC=2)Cl)CCC(F)(F)CC1 YUZMKQKVLJEEJJ-UHFFFAOYSA-N 0.000 claims 1
- NBTYBSNXBADVPU-UHFFFAOYSA-N 2,4-dichloro-n-[2-phenyl-2-[6-(trifluoromethyl)pyridin-3-yl]ethyl]benzamide Chemical compound C1=NC(C(F)(F)F)=CC=C1C(C=1C=CC=CC=1)CNC(=O)C1=CC=C(Cl)C=C1Cl NBTYBSNXBADVPU-UHFFFAOYSA-N 0.000 claims 1
- XWEMSXOCKDYDPD-UHFFFAOYSA-N 2-chloro-3-fluoro-N-[1-[4-(2-methylpyrimidin-5-yl)oxan-4-yl]ethyl]benzamide Chemical compound ClC1=C(C(=O)NC(C)C2(CCOCC2)C=2C=NC(=NC2)C)C=CC=C1F XWEMSXOCKDYDPD-UHFFFAOYSA-N 0.000 claims 1
- QEYKDQHFRMNKGH-UHFFFAOYSA-N 2-chloro-3-fluoro-n-[2-(2-methylpyrimidin-5-yl)-2-(oxan-4-yl)ethyl]benzamide Chemical compound C1=NC(C)=NC=C1C(C1CCOCC1)CNC(=O)C1=CC=CC(F)=C1Cl QEYKDQHFRMNKGH-UHFFFAOYSA-N 0.000 claims 1
- HZECEGAQKXABBD-UHFFFAOYSA-N 2-chloro-3-fluoro-n-[2-(2-methylpyrimidin-5-yl)-2-pyridin-4-ylethyl]benzamide Chemical compound C1=NC(C)=NC=C1C(C=1C=CN=CC=1)CNC(=O)C1=CC=CC(F)=C1Cl HZECEGAQKXABBD-UHFFFAOYSA-N 0.000 claims 1
- KBQRAZHZDJPPTQ-UHFFFAOYSA-N 2-chloro-3-fluoro-n-[2-(4-fluorophenyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide Chemical compound C1=CC(F)=CC=C1C(C=1C=NC(=NC=1)C(F)(F)F)CNC(=O)C1=CC=CC(F)=C1Cl KBQRAZHZDJPPTQ-UHFFFAOYSA-N 0.000 claims 1
- MQWUFPQPJYHBKY-UHFFFAOYSA-N 2-chloro-6-fluoro-N-[1-[4-(2-methylpyrimidin-5-yl)oxan-4-yl]ethyl]benzamide Chemical compound ClC1=C(C(=O)NC(C)C2(CCOCC2)C=2C=NC(=NC2)C)C(=CC=C1)F MQWUFPQPJYHBKY-UHFFFAOYSA-N 0.000 claims 1
- JSKYVDGKVXCBLD-UHFFFAOYSA-N 2-chloro-6-fluoro-n-[2-(2-methylpyrimidin-5-yl)-2-(oxan-4-yl)ethyl]benzamide Chemical compound C1=NC(C)=NC=C1C(C1CCOCC1)CNC(=O)C1=C(F)C=CC=C1Cl JSKYVDGKVXCBLD-UHFFFAOYSA-N 0.000 claims 1
- XXMSRMYYFQGTNN-UHFFFAOYSA-N 2-chloro-6-fluoro-n-[2-(2-methylpyrimidin-5-yl)-2-pyridin-4-ylethyl]benzamide Chemical compound C1=NC(C)=NC=C1C(C=1C=CN=CC=1)CNC(=O)C1=C(F)C=CC=C1Cl XXMSRMYYFQGTNN-UHFFFAOYSA-N 0.000 claims 1
- NTYHFLCIEDUDEI-UHFFFAOYSA-N 2-chloro-6-fluoro-n-[[4-[2-(trifluoromethyl)pyrimidin-5-yl]oxan-4-yl]methyl]benzamide Chemical compound FC1=CC=CC(Cl)=C1C(=O)NCC1(C=2C=NC(=NC=2)C(F)(F)F)CCOCC1 NTYHFLCIEDUDEI-UHFFFAOYSA-N 0.000 claims 1
- AWXJRWFNWOWRDT-UHFFFAOYSA-N 2-chloro-N-[1-[4,4-difluoro-1-(2-methylpyrimidin-5-yl)cyclohexyl]ethyl]-6-fluorobenzamide Chemical compound CC(NC(=O)c1c(F)cccc1Cl)C1(CCC(F)(F)CC1)c1cnc(C)nc1 AWXJRWFNWOWRDT-UHFFFAOYSA-N 0.000 claims 1
- BKYFLXQYYUSRIL-UHFFFAOYSA-N 2-chloro-n-[2-(2-methylpyrimidin-5-yl)-2-pyridin-4-ylethyl]benzamide Chemical compound C1=NC(C)=NC=C1C(C=1C=CN=CC=1)CNC(=O)C1=CC=CC=C1Cl BKYFLXQYYUSRIL-UHFFFAOYSA-N 0.000 claims 1
- RQOQZSKCNHLSMV-UHFFFAOYSA-N 2-chloro-n-[2-(2-methylpyrimidin-5-yl)-3-[1-(trifluoromethyl)cyclopropyl]propyl]benzamide Chemical compound C1=NC(C)=NC=C1C(CC1(CC1)C(F)(F)F)CNC(=O)C1=CC=CC=C1Cl RQOQZSKCNHLSMV-UHFFFAOYSA-N 0.000 claims 1
- PDYWWWPDYNSJPI-UHFFFAOYSA-N 2-chloro-n-[2-(4,4-difluorocyclohexyl)-2-(2-methylpyrimidin-5-yl)ethyl]benzamide Chemical compound C1=NC(C)=NC=C1C(C1CCC(F)(F)CC1)CNC(=O)C1=CC=CC=C1Cl PDYWWWPDYNSJPI-UHFFFAOYSA-N 0.000 claims 1
- WEBMYSIDXGVBKP-UHFFFAOYSA-N 2-chloro-n-[2-pyridin-4-yl-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide Chemical compound C1=NC(C(F)(F)F)=NC=C1C(C=1C=CN=CC=1)CNC(=O)C1=CC=CC=C1Cl WEBMYSIDXGVBKP-UHFFFAOYSA-N 0.000 claims 1
- UIGGFHHHBJIJNF-UHFFFAOYSA-N 2-chloro-n-[3-[1-(trifluoromethyl)cyclopropyl]-2-[2-(trifluoromethyl)pyrimidin-5-yl]propyl]benzamide Chemical compound C1=NC(C(F)(F)F)=NC=C1C(CC1(CC1)C(F)(F)F)CNC(=O)C1=CC=CC=C1Cl UIGGFHHHBJIJNF-UHFFFAOYSA-N 0.000 claims 1
- JKVUCJDDKNGCOP-UHFFFAOYSA-N 2-chloro-n-[3-cyclopropyl-2-[2-(trifluoromethyl)pyrimidin-5-yl]propyl]-6-fluorobenzamide Chemical compound FC1=CC=CC(Cl)=C1C(=O)NCC(C=1C=NC(=NC=1)C(F)(F)F)CC1CC1 JKVUCJDDKNGCOP-UHFFFAOYSA-N 0.000 claims 1
- WMAJFKXCZGWJEI-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-(2-methylpyrimidin-5-yl)cyclohexyl]methyl]benzamide Chemical compound C1=NC(C)=NC=C1C1(CNC(=O)C=2C(=CC=CC=2)Cl)CCC(F)(F)CC1 WMAJFKXCZGWJEI-UHFFFAOYSA-N 0.000 claims 1
- LPWLZWUKERRESP-UHFFFAOYSA-N ClC1=C(C(=O)NCC(CC2(CC2)F)C=2C=NC(=NC2)C(F)(F)F)C=CC=C1Cl Chemical compound ClC1=C(C(=O)NCC(CC2(CC2)F)C=2C=NC(=NC2)C(F)(F)F)C=CC=C1Cl LPWLZWUKERRESP-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 38
- 208000035475 disorder Diseases 0.000 abstract description 24
- 208000002193 Pain Diseases 0.000 abstract description 14
- 208000012902 Nervous system disease Diseases 0.000 abstract description 10
- 230000036407 pain Effects 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 208000025966 Neurological disease Diseases 0.000 abstract description 4
- 238000000034 method Methods 0.000 description 422
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 400
- 239000000203 mixture Substances 0.000 description 185
- 239000000243 solution Substances 0.000 description 108
- QAOJBHRZQQDFHA-UHFFFAOYSA-N 2,3-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1Cl QAOJBHRZQQDFHA-UHFFFAOYSA-N 0.000 description 83
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 72
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 67
- 238000006243 chemical reaction Methods 0.000 description 67
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- 229910052938 sodium sulfate Inorganic materials 0.000 description 64
- 235000011152 sodium sulphate Nutrition 0.000 description 64
- 101150041968 CDC13 gene Proteins 0.000 description 62
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 62
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 62
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 60
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 58
- 239000012044 organic layer Substances 0.000 description 57
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 55
- 239000011541 reaction mixture Substances 0.000 description 54
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 50
- 238000005160 1H NMR spectroscopy Methods 0.000 description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- 239000007832 Na2SO4 Substances 0.000 description 46
- 230000002829 reductive effect Effects 0.000 description 46
- 239000012267 brine Substances 0.000 description 45
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 44
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- 239000012043 crude product Substances 0.000 description 41
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 39
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 38
- WJYAYXKXZNITAZ-UHFFFAOYSA-N 2-chloro-3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1Cl WJYAYXKXZNITAZ-UHFFFAOYSA-N 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 31
- 239000000741 silica gel Substances 0.000 description 28
- 229910002027 silica gel Inorganic materials 0.000 description 28
- UENGBOCGGKLVJJ-UHFFFAOYSA-N 2-chloro-1-(2,4-difluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CCl)C(F)=C1 UENGBOCGGKLVJJ-UHFFFAOYSA-N 0.000 description 27
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
- 238000004440 column chromatography Methods 0.000 description 24
- 239000003208 petroleum Substances 0.000 description 24
- 239000000543 intermediate Substances 0.000 description 23
- 238000000746 purification Methods 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- XNTIGDVFBDJLTQ-UHFFFAOYSA-N 2-chloro-6-fluorobenzoic acid Chemical compound OC(=O)C1=C(F)C=CC=C1Cl XNTIGDVFBDJLTQ-UHFFFAOYSA-N 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 150000001408 amides Chemical class 0.000 description 21
- 238000003818 flash chromatography Methods 0.000 description 21
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 21
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 21
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 20
- 239000010410 layer Substances 0.000 description 19
- ATCRIUVQKHMXSH-UHFFFAOYSA-N 2,4-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1Cl ATCRIUVQKHMXSH-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 17
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 17
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 17
- 208000019022 Mood disease Diseases 0.000 description 16
- 239000002253 acid Substances 0.000 description 16
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 16
- 238000003756 stirring Methods 0.000 description 15
- MRUDNSFOFOQZDA-UHFFFAOYSA-N 2,6-dichlorobenzoic acid Chemical compound OC(=O)C1=C(Cl)C=CC=C1Cl MRUDNSFOFOQZDA-UHFFFAOYSA-N 0.000 description 14
- KGGHWIKBOIQEAJ-UHFFFAOYSA-N 2-fluorobenzamide Chemical compound NC(=O)C1=CC=CC=C1F KGGHWIKBOIQEAJ-UHFFFAOYSA-N 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- VIUDWLLKFANPLX-UHFFFAOYSA-N 2-chloro-3-methoxybenzoic acid Chemical compound COC1=CC=CC(C(O)=O)=C1Cl VIUDWLLKFANPLX-UHFFFAOYSA-N 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- 238000005984 hydrogenation reaction Methods 0.000 description 11
- 239000003643 water by type Substances 0.000 description 11
- 208000017194 Affective disease Diseases 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 125000004076 pyridyl group Chemical group 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 7
- 208000024714 major depressive disease Diseases 0.000 description 7
- 208000015122 neurodegenerative disease Diseases 0.000 description 7
- 239000012279 sodium borohydride Substances 0.000 description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- LEBWXJZAWTVKFL-UHFFFAOYSA-N 2-chloro-5-methylbenzoic acid Chemical compound CC1=CC=C(Cl)C(C(O)=O)=C1 LEBWXJZAWTVKFL-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 6
- 239000007868 Raney catalyst Substances 0.000 description 6
- 229910000564 Raney nickel Inorganic materials 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 238000000132 electrospray ionisation Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 208000028173 post-traumatic stress disease Diseases 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- RIZUCYSQUWMQLX-UHFFFAOYSA-N 2,3-dimethylbenzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1C RIZUCYSQUWMQLX-UHFFFAOYSA-N 0.000 description 4
- HLLIGPMLEFXSPO-UHFFFAOYSA-N 2-(2-methylpyrimidin-5-yl)acetonitrile Chemical compound CC1=NC=C(CC#N)C=N1 HLLIGPMLEFXSPO-UHFFFAOYSA-N 0.000 description 4
- MNWSGMTUGXNYHJ-UHFFFAOYSA-N 2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(N)=O MNWSGMTUGXNYHJ-UHFFFAOYSA-N 0.000 description 4
- IJBONYUNKRDIFC-UHFFFAOYSA-N 2-methylpyrimidine-5-carbaldehyde Chemical compound CC1=NC=C(C=O)C=N1 IJBONYUNKRDIFC-UHFFFAOYSA-N 0.000 description 4
- AWJJLYZBWRIBCZ-UGTJMOTHSA-N 3'-O-(4-Benzoyl)benzoyl ATP Chemical compound O([C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)N1C=2N=CN=C(C=2N=C1)N)C(=O)C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 AWJJLYZBWRIBCZ-UGTJMOTHSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- FCSSYEWURMTUSM-UHFFFAOYSA-N 3-chloro-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1F FCSSYEWURMTUSM-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical compound COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- SVKJOUIZQRKDAI-UHFFFAOYSA-N difluoromethanesulfinic acid;zinc Chemical compound [Zn].OS(=O)C(F)F.OS(=O)C(F)F SVKJOUIZQRKDAI-UHFFFAOYSA-N 0.000 description 4
- 238000000105 evaporative light scattering detection Methods 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 229940100684 pentylamine Drugs 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- AAPLIUHOKVUFCC-UHFFFAOYSA-N trimethylsilanol Chemical compound C[Si](C)(C)O AAPLIUHOKVUFCC-UHFFFAOYSA-N 0.000 description 4
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 4
- IDLJEJIHDBHTEO-UHFFFAOYSA-N 1-(bromomethyl)-1-(trifluoromethyl)cyclopropane Chemical compound FC(F)(F)C1(CBr)CC1 IDLJEJIHDBHTEO-UHFFFAOYSA-N 0.000 description 3
- BJESGTSIBDMSPY-UHFFFAOYSA-N 1-[4-(2-methylpyrimidin-5-yl)oxan-4-yl]ethanone Chemical compound C=1N=C(C)N=CC=1C1(C(=O)C)CCOCC1 BJESGTSIBDMSPY-UHFFFAOYSA-N 0.000 description 3
- 238000004293 19F NMR spectroscopy Methods 0.000 description 3
- LRBKIKHNHHXLGG-UHFFFAOYSA-N 2-(4,4-difluorocyclohexylidene)-2-(2-methylpyrimidin-5-yl)acetonitrile Chemical compound C1=NC(C)=NC=C1C(C#N)=C1CCC(F)(F)CC1 LRBKIKHNHHXLGG-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- NSTREUWFTAOOKS-UHFFFAOYSA-N 2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1F NSTREUWFTAOOKS-UHFFFAOYSA-N 0.000 description 3
- XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical compound CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 description 3
- ABHBVZFGGJTZDY-UHFFFAOYSA-N 4-(2-methylpyrimidin-5-yl)oxane-4-carbonitrile Chemical compound C1=NC(C)=NC=C1C1(C#N)CCOCC1 ABHBVZFGGJTZDY-UHFFFAOYSA-N 0.000 description 3
- KWVLNPQHGPJNIJ-UHFFFAOYSA-N 4-(2-methylpyrimidin-5-yl)oxane-4-carboxylic acid Chemical compound C1=NC(C)=NC=C1C1(C(O)=O)CCOCC1 KWVLNPQHGPJNIJ-UHFFFAOYSA-N 0.000 description 3
- FFVULVBNSFTNFM-UHFFFAOYSA-N 4-[4-(trifluoromethyl)phenyl]oxane-4-carbonitrile Chemical compound C1=CC(C(F)(F)F)=CC=C1C1(C#N)CCOCC1 FFVULVBNSFTNFM-UHFFFAOYSA-N 0.000 description 3
- DQWIPVDHLUQZBV-UHFFFAOYSA-N 4-benzylpyridazine Chemical compound C=1C=NN=CC=1CC1=CC=CC=C1 DQWIPVDHLUQZBV-UHFFFAOYSA-N 0.000 description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 101001098175 Homo sapiens P2X purinoceptor 7 Proteins 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000610375 Sparisoma viride Species 0.000 description 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 3
- KOVSLEUZAOEDFI-UHFFFAOYSA-N [4-(2-methylpyrimidin-5-yl)oxan-4-yl]methanamine Chemical compound C1=NC(C)=NC=C1C1(CN)CCOCC1 KOVSLEUZAOEDFI-UHFFFAOYSA-N 0.000 description 3
- 229940048053 acrylate Drugs 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- GYPLOZFHFXKSRM-UHFFFAOYSA-N ethyl 3-phenyl-3-pyridazin-4-ylpropanoate Chemical compound C=1C=NN=CC=1C(CC(=O)OCC)C1=CC=CC=C1 GYPLOZFHFXKSRM-UHFFFAOYSA-N 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- TVUWLLCWQGXPSH-UHFFFAOYSA-N methyl 5-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CN=CC(Cl)=C1 TVUWLLCWQGXPSH-UHFFFAOYSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000011698 potassium fluoride Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 3
- 229940086542 triethylamine Drugs 0.000 description 3
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- AYGXRNZDYVFABZ-UHFFFAOYSA-N 1-(1-fluorocyclopropyl)ethanone Chemical compound CC(=O)C1(F)CC1 AYGXRNZDYVFABZ-UHFFFAOYSA-N 0.000 description 2
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 2
- DOTMBVFQYWPMGW-UHFFFAOYSA-N 1-[4,4-difluoro-1-(2-methylpyrimidin-5-yl)cyclohexyl]ethanone Chemical compound C=1N=C(C)N=CC=1C1(C(=O)C)CCC(F)(F)CC1 DOTMBVFQYWPMGW-UHFFFAOYSA-N 0.000 description 2
- NDCPERCVXDYEFU-UHFFFAOYSA-N 1-fluorocyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(F)CC1 NDCPERCVXDYEFU-UHFFFAOYSA-N 0.000 description 2
- LBQMIAVIGLLBGW-UHFFFAOYSA-N 2,5-difluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1F LBQMIAVIGLLBGW-UHFFFAOYSA-N 0.000 description 2
- ONOTYLMNTZNAQZ-UHFFFAOYSA-N 2,6-difluorobenzoic acid Chemical compound OC(=O)C1=C(F)C=CC=C1F ONOTYLMNTZNAQZ-UHFFFAOYSA-N 0.000 description 2
- RXHUXDNPKIRRHE-UHFFFAOYSA-N 2-(2-methylpyrimidin-5-yl)-2-propan-2-yloxyethanamine Chemical compound CC(C)OC(CN)C1=CN=C(C)N=C1 RXHUXDNPKIRRHE-UHFFFAOYSA-N 0.000 description 2
- VWTOQDTZHINQAA-UHFFFAOYSA-N 2-(2-methylpyrimidin-5-yl)oxolane-2-carbonitrile Chemical compound C1=NC(C)=NC=C1C1(C#N)OCCC1 VWTOQDTZHINQAA-UHFFFAOYSA-N 0.000 description 2
- XKDAZGBGXQWAHM-UHFFFAOYSA-N 2-(3-bromopropoxy)-2-(2-methylpyrimidin-5-yl)acetonitrile Chemical compound CC1=NC=C(C(OCCCBr)C#N)C=N1 XKDAZGBGXQWAHM-UHFFFAOYSA-N 0.000 description 2
- CXCZPHUOZMSYCT-UHFFFAOYSA-N 2-(4,4-difluorocyclohexyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethanamine Chemical compound C=1N=C(C(F)(F)F)N=CC=1C(CN)C1CCC(F)(F)CC1 CXCZPHUOZMSYCT-UHFFFAOYSA-N 0.000 description 2
- PNKKPFLBOWGVSF-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-phenylethanamine Chemical compound C=1C=C(Cl)C=CC=1C(CN)C1=CC=CC=C1 PNKKPFLBOWGVSF-UHFFFAOYSA-N 0.000 description 2
- QBAYIBZITZBSFO-UHFFFAOYSA-N 2-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=CC=C1C(F)(F)F QBAYIBZITZBSFO-UHFFFAOYSA-N 0.000 description 2
- AXOAWWUSRZCGKS-UHFFFAOYSA-N 2-chloro-3-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=C1Cl AXOAWWUSRZCGKS-UHFFFAOYSA-N 0.000 description 2
- SKWDIXBVQATQSG-UHFFFAOYSA-N 2-chloro-5-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=C(Cl)C(C(O)=O)=C1 SKWDIXBVQATQSG-UHFFFAOYSA-N 0.000 description 2
- DTNSDCJFTHMDAK-UHFFFAOYSA-N 2-cyanobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C#N DTNSDCJFTHMDAK-UHFFFAOYSA-N 0.000 description 2
- YNNKCQOXTRETIS-UHFFFAOYSA-N 2-phenyl-2-pyridazin-4-ylethanamine Chemical compound C=1C=NN=CC=1C(CN)C1=CC=CC=C1 YNNKCQOXTRETIS-UHFFFAOYSA-N 0.000 description 2
- YJBYWKDEVMXEGG-UHFFFAOYSA-N 3-acetyl-3-fluorooxolan-2-one Chemical compound CC(=O)C1(F)CCOC1=O YJBYWKDEVMXEGG-UHFFFAOYSA-N 0.000 description 2
- JPCISVSOTKMFPG-UHFFFAOYSA-N 3-methoxy-2-methylbenzoic acid Chemical compound COC1=CC=CC(C(O)=O)=C1C JPCISVSOTKMFPG-UHFFFAOYSA-N 0.000 description 2
- KOFWUFBIMRYPGG-UHFFFAOYSA-N 4,4-difluoro-1-(2-methylpyrimidin-5-yl)cyclohexane-1-carboxylic acid Chemical compound C1=NC(C)=NC=C1C1(C(O)=O)CCC(F)(F)CC1 KOFWUFBIMRYPGG-UHFFFAOYSA-N 0.000 description 2
- NYYSPVRERVXMLJ-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-one Chemical compound FC1(F)CCC(=O)CC1 NYYSPVRERVXMLJ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 2
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 2
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 2
- JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 description 2
- NOUAHLUOQRHIBT-UHFFFAOYSA-N 5-[di(propan-2-yloxy)methyl]-2-methylpyrimidine Chemical compound CC(C)OC(OC(C)C)C1=CN=C(C)N=C1 NOUAHLUOQRHIBT-UHFFFAOYSA-N 0.000 description 2
- RPFAUCIXZGMCFN-UHFFFAOYSA-N 5-bromo-2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Br)C=N1 RPFAUCIXZGMCFN-UHFFFAOYSA-N 0.000 description 2
- GIFDWXWNFKZVEI-UHFFFAOYSA-N 5-bromo-2-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=NC=C(Br)C=N1 GIFDWXWNFKZVEI-UHFFFAOYSA-N 0.000 description 2
- 238000012815 AlphaLISA Methods 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- XCDSWMUPTXJTEY-UHFFFAOYSA-N FC(F)C1(CBr)CC1 Chemical compound FC(F)C1(CBr)CC1 XCDSWMUPTXJTEY-UHFFFAOYSA-N 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 101100135293 Mus musculus P2rx7 gene Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 101001098238 Rattus norvegicus P2X purinoceptor 7 Proteins 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- UFOVQRXKHPQEJG-UHFFFAOYSA-N [2-(2-methylpyrimidin-5-yl)oxolan-2-yl]methanamine Chemical compound C1=NC(C)=NC=C1C1(CN)OCCC1 UFOVQRXKHPQEJG-UHFFFAOYSA-N 0.000 description 2
- MIPUNIMXSFJARK-UHFFFAOYSA-N [4,4-difluoro-1-[6-(trifluoromethyl)pyridin-3-yl]cyclohexyl]methanamine Chemical compound C=1C=C(C(F)(F)F)N=CC=1C1(CN)CCC(F)(F)CC1 MIPUNIMXSFJARK-UHFFFAOYSA-N 0.000 description 2
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- SGJSQQLUMMGQOS-UHFFFAOYSA-N cyclohexanecarbonitrile Chemical compound N#C[C]1CCCCC1 SGJSQQLUMMGQOS-UHFFFAOYSA-N 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- FDZLCIITHLSEQK-UHFFFAOYSA-N ethyl 1-cyanocyclopropane-1-carboxylate Chemical compound CCOC(=O)C1(C#N)CC1 FDZLCIITHLSEQK-UHFFFAOYSA-N 0.000 description 2
- JSBSBOIAHOITDX-UHFFFAOYSA-N ethyl 1-formylcyclopropane-1-carboxylate Chemical compound CCOC(=O)C1(C=O)CC1 JSBSBOIAHOITDX-UHFFFAOYSA-N 0.000 description 2
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- IKGLACJFEHSFNN-UHFFFAOYSA-N hydron;triethylazanium;trifluoride Chemical compound F.F.F.CCN(CC)CC IKGLACJFEHSFNN-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- DBTNVRCCIDISMV-UHFFFAOYSA-L lithium;magnesium;propane;dichloride Chemical compound [Li+].[Mg+2].[Cl-].[Cl-].C[CH-]C DBTNVRCCIDISMV-UHFFFAOYSA-L 0.000 description 2
- MKPUZSPUUYTDNW-UHFFFAOYSA-N methyl 5-cyano-2-hydroxy-5-(2-methylpyrimidin-5-yl)cyclohexene-1-carboxylate Chemical compound C1C(C(=O)OC)=C(O)CCC1(C#N)C1=CN=C(C)N=C1 MKPUZSPUUYTDNW-UHFFFAOYSA-N 0.000 description 2
- IQQDLHGWGKEQDS-UHFFFAOYSA-N methyl hept-2-enoate Chemical compound CCCCC=CC(=O)OC IQQDLHGWGKEQDS-UHFFFAOYSA-N 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- XVJZQDQKVYSMFJ-UHFFFAOYSA-N phenyl(pyridazin-4-yl)methanone Chemical compound C=1C=NN=CC=1C(=O)C1=CC=CC=C1 XVJZQDQKVYSMFJ-UHFFFAOYSA-N 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229910001495 sodium tetrafluoroborate Inorganic materials 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- DBMSQZGNHNPNRT-UHFFFAOYSA-N tert-butyl n-(2-phenyl-2-pyridazin-4-ylethyl)carbamate Chemical compound C=1C=NN=CC=1C(CNC(=O)OC(C)(C)C)C1=CC=CC=C1 DBMSQZGNHNPNRT-UHFFFAOYSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- VIKFTRZVEVXPFI-UHFFFAOYSA-N (1-pyridin-3-ylcyclopentyl)methanamine Chemical compound C=1C=CN=CC=1C1(CN)CCCC1 VIKFTRZVEVXPFI-UHFFFAOYSA-N 0.000 description 1
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- SKCBKBCACWDALV-UHFFFAOYSA-N 1-(trifluoromethyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(C(F)(F)F)CC1 SKCBKBCACWDALV-UHFFFAOYSA-N 0.000 description 1
- FOZVXADQAHVUSV-UHFFFAOYSA-N 1-bromo-2-(2-bromoethoxy)ethane Chemical compound BrCCOCCBr FOZVXADQAHVUSV-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- ARMNMUCAIHEYDB-UHFFFAOYSA-N 1-ethoxyethenyltin Chemical compound CCOC([Sn])=C ARMNMUCAIHEYDB-UHFFFAOYSA-N 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- GELFWLSHOSXXRT-UHFFFAOYSA-N 1-pyridin-3-ylcyclopentane-1-carbonitrile Chemical compound C=1C=CN=CC=1C1(C#N)CCCC1 GELFWLSHOSXXRT-UHFFFAOYSA-N 0.000 description 1
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 1
- CPZROMDDCPPFOO-UHFFFAOYSA-N 2,3,5-trifluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC(F)=C1F CPZROMDDCPPFOO-UHFFFAOYSA-N 0.000 description 1
- PTGJKVLZGTXXJQ-UHFFFAOYSA-N 2,3-dichloro-n-[(1-pyridin-3-ylcyclopentyl)methyl]benzamide Chemical compound ClC1=CC=CC(C(=O)NCC2(CCCC2)C=2C=NC=CC=2)=C1Cl PTGJKVLZGTXXJQ-UHFFFAOYSA-N 0.000 description 1
- PDYROJQABWKPAA-UHFFFAOYSA-N 2,3-dichloro-n-[2-(2-methylpyrimidin-5-yl)-2-propan-2-yloxyethyl]benzamide Chemical compound C=1N=C(C)N=CC=1C(OC(C)C)CNC(=O)C1=CC=CC(Cl)=C1Cl PDYROJQABWKPAA-UHFFFAOYSA-N 0.000 description 1
- SMCKEZRORVPHFF-UHFFFAOYSA-N 2,3-dichloro-n-[2-(4-chlorophenyl)-2-phenylethyl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)CNC(=O)C1=CC=CC(Cl)=C1Cl SMCKEZRORVPHFF-UHFFFAOYSA-N 0.000 description 1
- DCHNTHLPEZQFHZ-UHFFFAOYSA-N 2,3-dichloro-n-[[1-[2-(difluoromethyl)pyrimidin-5-yl]-4,4-difluorocyclohexyl]methyl]benzamide Chemical compound C1=NC(C(F)F)=NC=C1C1(CNC(=O)C=2C(=C(Cl)C=CC=2)Cl)CCC(F)(F)CC1 DCHNTHLPEZQFHZ-UHFFFAOYSA-N 0.000 description 1
- UZKXTPHGWOFFHL-UHFFFAOYSA-N 2,3-dichloro-n-[[4,4-difluoro-1-(6-fluoropyridin-3-yl)cyclohexyl]methyl]benzamide Chemical compound C1=NC(F)=CC=C1C1(CNC(=O)C=2C(=C(Cl)C=CC=2)Cl)CCC(F)(F)CC1 UZKXTPHGWOFFHL-UHFFFAOYSA-N 0.000 description 1
- KZKYRHRAVGWEAV-UHFFFAOYSA-N 2,3-dichlorobenzamide Chemical compound NC(=O)C1=CC=CC(Cl)=C1Cl KZKYRHRAVGWEAV-UHFFFAOYSA-N 0.000 description 1
- YBONBWJSFMTXLE-UHFFFAOYSA-N 2,3-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Cl)=C1Cl YBONBWJSFMTXLE-UHFFFAOYSA-N 0.000 description 1
- JLZVIWSFUPLSOR-UHFFFAOYSA-N 2,3-difluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1F JLZVIWSFUPLSOR-UHFFFAOYSA-N 0.000 description 1
- JRLGQGZOMQMOCF-UHFFFAOYSA-N 2,3-dimethyl-n-[(1-pyridin-3-ylcyclopentyl)methyl]benzamide Chemical compound CC1=CC=CC(C(=O)NCC2(CCCC2)C=2C=NC=CC=2)=C1C JRLGQGZOMQMOCF-UHFFFAOYSA-N 0.000 description 1
- IZAYISYTIWLBNB-UHFFFAOYSA-N 2,3-dimethylbenzamide Chemical compound CC1=CC=CC(C(N)=O)=C1C IZAYISYTIWLBNB-UHFFFAOYSA-N 0.000 description 1
- WFNKMVDATNLZBX-UHFFFAOYSA-N 2,3-dimethylbenzoyl chloride Chemical compound CC1=CC=CC(C(Cl)=O)=C1C WFNKMVDATNLZBX-UHFFFAOYSA-N 0.000 description 1
- WWHRVRBFSIGTHY-UHFFFAOYSA-N 2,4-dichloro-n-(2-phenyl-2-pyridazin-4-ylethyl)benzamide Chemical compound ClC1=CC(Cl)=CC=C1C(=O)NCC(C=1C=NN=CC=1)C1=CC=CC=C1 WWHRVRBFSIGTHY-UHFFFAOYSA-N 0.000 description 1
- QVTQYSFCFOGITD-UHFFFAOYSA-N 2,5-dichlorobenzoic acid Chemical compound OC(=O)C1=CC(Cl)=CC=C1Cl QVTQYSFCFOGITD-UHFFFAOYSA-N 0.000 description 1
- XYCNEYHKHNDVPJ-UHFFFAOYSA-N 2,6-dichloro-n-[[1-[2-(difluoromethyl)pyrimidin-5-yl]-4,4-difluorocyclohexyl]methyl]benzamide Chemical compound C1=NC(C(F)F)=NC=C1C1(CNC(=O)C=2C(=CC=CC=2Cl)Cl)CCC(F)(F)CC1 XYCNEYHKHNDVPJ-UHFFFAOYSA-N 0.000 description 1
- FUJSJWRORKKPAI-UHFFFAOYSA-N 2-(2,4-dichlorophenoxy)acetyl chloride Chemical compound ClC(=O)COC1=CC=C(Cl)C=C1Cl FUJSJWRORKKPAI-UHFFFAOYSA-N 0.000 description 1
- JKHJZYWBFOGMLL-UHFFFAOYSA-N 2-(2-methylpyrimidin-5-yl)-2-propan-2-yloxyacetonitrile Chemical compound CC(C)OC(C#N)C1=CN=C(C)N=C1 JKHJZYWBFOGMLL-UHFFFAOYSA-N 0.000 description 1
- YNTJKQDWYXUTLZ-UHFFFAOYSA-N 2-(3-chlorophenoxy)propanoic acid Chemical compound OC(=O)C(C)OC1=CC=CC(Cl)=C1 YNTJKQDWYXUTLZ-UHFFFAOYSA-N 0.000 description 1
- YRYGEJKOAAYMCH-UHFFFAOYSA-N 2-(3-hydroxypropoxy)-2-(2-methylpyrimidin-5-yl)acetonitrile Chemical compound CC1=NC=C(C(OCCCO)C#N)C=N1 YRYGEJKOAAYMCH-UHFFFAOYSA-N 0.000 description 1
- FEWQGNVIIFBGFC-UHFFFAOYSA-N 2-(4,4-difluorocyclohexyl)-2-(2-methylpyrimidin-5-yl)ethanamine Chemical compound C1=NC(C)=NC=C1C(CN)C1CCC(F)(F)CC1 FEWQGNVIIFBGFC-UHFFFAOYSA-N 0.000 description 1
- IWVFHDSZVODKIB-UHFFFAOYSA-N 2-(4-chlorophenyl)-4-(dimethylamino)butanenitrile Chemical compound CN(C)CCC(C#N)C1=CC=C(Cl)C=C1 IWVFHDSZVODKIB-UHFFFAOYSA-N 0.000 description 1
- AAZBJHANSZZHKF-UHFFFAOYSA-N 2-(4-chlorophenyl)-n',n'-dimethylbutane-1,4-diamine Chemical compound CN(C)CCC(CN)C1=CC=C(Cl)C=C1 AAZBJHANSZZHKF-UHFFFAOYSA-N 0.000 description 1
- JHQBLYITVCBGTO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetonitrile Chemical compound FC1=CC=C(CC#N)C=C1 JHQBLYITVCBGTO-UHFFFAOYSA-N 0.000 description 1
- BLGUCBUETMYJTB-UHFFFAOYSA-N 2-(6-chloropyridin-3-yl)acetonitrile Chemical compound ClC1=CC=C(CC#N)C=N1 BLGUCBUETMYJTB-UHFFFAOYSA-N 0.000 description 1
- UJJMLGJZQGGQAZ-UHFFFAOYSA-N 2-(fluoromethyl)pyridine Chemical compound FCC1=CC=CC=N1 UJJMLGJZQGGQAZ-UHFFFAOYSA-N 0.000 description 1
- JODOPUQOPMDOFT-UHFFFAOYSA-N 2-[2-(trifluoromethyl)pyrimidin-5-yl]acetonitrile Chemical compound FC(F)(F)C1=NC=C(CC#N)C=N1 JODOPUQOPMDOFT-UHFFFAOYSA-N 0.000 description 1
- QNKOCFJZJWOXDE-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]acetonitrile Chemical compound FC(F)(F)C1=CC=C(CC#N)C=C1 QNKOCFJZJWOXDE-UHFFFAOYSA-N 0.000 description 1
- CZKOUYKBXFNMES-UHFFFAOYSA-N 2-[5-(1-amino-3-cyclopropylpropan-2-yl)pyridin-2-yl]propan-2-ol Chemical compound C1=NC(C(C)(O)C)=CC=C1C(CN)CC1CC1 CZKOUYKBXFNMES-UHFFFAOYSA-N 0.000 description 1
- MUURVYOEMFYHRI-UHFFFAOYSA-N 2-[6-(trifluoromethyl)pyridin-3-yl]acetonitrile Chemical compound FC(F)(F)C1=CC=C(CC#N)C=N1 MUURVYOEMFYHRI-UHFFFAOYSA-N 0.000 description 1
- FPIVAWNGRDHRSQ-UHFFFAOYSA-N 2-[di(propan-2-yloxy)methoxy]propane Chemical compound CC(C)OC(OC(C)C)OC(C)C FPIVAWNGRDHRSQ-UHFFFAOYSA-N 0.000 description 1
- OLSXHZBPBDUBHZ-UHFFFAOYSA-N 2-chloro-3-fluoro-n-[[4-(2-methylpyrimidin-5-yl)oxan-4-yl]methyl]benzamide Chemical compound C1=NC(C)=NC=C1C1(CNC(=O)C=2C(=C(F)C=CC=2)Cl)CCOCC1 OLSXHZBPBDUBHZ-UHFFFAOYSA-N 0.000 description 1
- LWOKLXMNGXXORN-UHFFFAOYSA-N 2-chloro-3-methylbenzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1Cl LWOKLXMNGXXORN-UHFFFAOYSA-N 0.000 description 1
- GRPWQLDSGNZEQE-UHFFFAOYSA-N 2-chloro-4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1Cl GRPWQLDSGNZEQE-UHFFFAOYSA-N 0.000 description 1
- CTTWSFIIFMWHLQ-UHFFFAOYSA-N 2-chloro-4-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=C(C(O)=O)C(Cl)=C1 CTTWSFIIFMWHLQ-UHFFFAOYSA-N 0.000 description 1
- WLXRKCGYQAKHSJ-UHFFFAOYSA-N 2-chloro-5-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(C(F)(F)F)=CC=C1Cl WLXRKCGYQAKHSJ-UHFFFAOYSA-N 0.000 description 1
- AQHFCRYZABKUEV-UHFFFAOYSA-N 2-chloro-5-methoxybenzoic acid Chemical compound COC1=CC=C(Cl)C(C(O)=O)=C1 AQHFCRYZABKUEV-UHFFFAOYSA-N 0.000 description 1
- BRBBOPAVAKEXHC-UHFFFAOYSA-N 2-chloro-5-methyl-n-[(1-pyridin-3-ylcyclopentyl)methyl]benzamide Chemical compound CC1=CC=C(Cl)C(C(=O)NCC2(CCCC2)C=2C=NC=CC=2)=C1 BRBBOPAVAKEXHC-UHFFFAOYSA-N 0.000 description 1
- LLMRANVEYOITJF-UHFFFAOYSA-N 2-chloro-n-[2-(2-methylpyrimidin-5-yl)-2-propan-2-yloxyethyl]benzamide Chemical compound C=1N=C(C)N=CC=1C(OC(C)C)CNC(=O)C1=CC=CC=C1Cl LLMRANVEYOITJF-UHFFFAOYSA-N 0.000 description 1
- MVAFJODGYSUZIL-UHFFFAOYSA-N 2-chloro-n-[2-phenyl-2-[6-(trifluoromethyl)pyridin-3-yl]ethyl]benzamide Chemical compound C1=NC(C(F)(F)F)=CC=C1C(C=1C=CC=CC=1)CNC(=O)C1=CC=CC=C1Cl MVAFJODGYSUZIL-UHFFFAOYSA-N 0.000 description 1
- JOCWFUMEUWIDBA-UHFFFAOYSA-N 2-chloro-n-[[1-[2-(difluoromethyl)pyrimidin-5-yl]-4,4-difluorocyclohexyl]methyl]benzamide Chemical compound C1=NC(C(F)F)=NC=C1C1(CNC(=O)C=2C(=CC=CC=2)Cl)CCC(F)(F)CC1 JOCWFUMEUWIDBA-UHFFFAOYSA-N 0.000 description 1
- XVEAMDNSCPPPCP-UHFFFAOYSA-N 2-fluoro-3-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=C1F XVEAMDNSCPPPCP-UHFFFAOYSA-N 0.000 description 1
- AVGWCJLTQZQLCN-UHFFFAOYSA-N 2-fluoro-3-methoxybenzoic acid Chemical compound COC1=CC=CC(C(O)=O)=C1F AVGWCJLTQZQLCN-UHFFFAOYSA-N 0.000 description 1
- DGNAETGARNTCIL-UHFFFAOYSA-N 2-fluoro-3-methylbenzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1F DGNAETGARNTCIL-UHFFFAOYSA-N 0.000 description 1
- REDSLTKMNCCQBC-UHFFFAOYSA-N 2-fluoro-5-methoxybenzoic acid Chemical compound COC1=CC=C(F)C(C(O)=O)=C1 REDSLTKMNCCQBC-UHFFFAOYSA-N 0.000 description 1
- YURNCBVQZBJDAJ-UHFFFAOYSA-N 2-heptenoic acid Chemical compound CCCCC=CC(O)=O YURNCBVQZBJDAJ-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- RZNHSEZOLFEFGB-UHFFFAOYSA-N 2-methoxybenzoyl chloride Chemical compound COC1=CC=CC=C1C(Cl)=O RZNHSEZOLFEFGB-UHFFFAOYSA-N 0.000 description 1
- OZRXZNCUIZXGPD-UHFFFAOYSA-N 2-methyl-n-[(1-methyl-4-phenylpiperidin-4-yl)methyl]benzamide Chemical compound C1CN(C)CCC1(C=1C=CC=CC=1)CNC(=O)C1=CC=CC=C1C OZRXZNCUIZXGPD-UHFFFAOYSA-N 0.000 description 1
- YZSHNJLAVFLXCZ-UHFFFAOYSA-N 2-methyl-n-[(1-pyridin-3-ylcyclopentyl)methyl]benzamide Chemical compound CC1=CC=CC=C1C(=O)NCC1(C=2C=NC=CC=2)CCCC1 YZSHNJLAVFLXCZ-UHFFFAOYSA-N 0.000 description 1
- GPZXFICWCMCQPF-UHFFFAOYSA-N 2-methylbenzoyl chloride Chemical compound CC1=CC=CC=C1C(Cl)=O GPZXFICWCMCQPF-UHFFFAOYSA-N 0.000 description 1
- CJKJNTJPOYSDQL-UHFFFAOYSA-N 2-methylsulfonylbenzamide Chemical compound CS(=O)(=O)C1=CC=CC=C1C(N)=O CJKJNTJPOYSDQL-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- WBXNRDHUHUWTDU-UHFFFAOYSA-N 2-pyrimidin-5-ylacetonitrile Chemical compound N#CCC1=CN=CN=C1 WBXNRDHUHUWTDU-UHFFFAOYSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- OMQHDIHZSDEIFH-UHFFFAOYSA-N 3-Acetyldihydro-2(3H)-furanone Chemical compound CC(=O)C1CCOC1=O OMQHDIHZSDEIFH-UHFFFAOYSA-N 0.000 description 1
- CYCRRRIREKXQTK-UHFFFAOYSA-N 3-acetyl-3-chlorooxolan-2-one Chemical compound CC(=O)C1(Cl)CCOC1=O CYCRRRIREKXQTK-UHFFFAOYSA-N 0.000 description 1
- BJGKVCKGUBYULR-UHFFFAOYSA-N 3-bromo-2-methylbenzoic acid Chemical compound CC1=C(Br)C=CC=C1C(O)=O BJGKVCKGUBYULR-UHFFFAOYSA-N 0.000 description 1
- HAVDOEUAXIXGLG-UHFFFAOYSA-N 3-chloro-n-[[4,4-difluoro-1-[6-(trifluoromethyl)pyridin-3-yl]cyclohexyl]methyl]-2-fluorobenzamide Chemical compound FC1=C(Cl)C=CC=C1C(=O)NCC1(C=2C=NC(=CC=2)C(F)(F)F)CCC(F)(F)CC1 HAVDOEUAXIXGLG-UHFFFAOYSA-N 0.000 description 1
- QPEFUCOMFYTEKE-UHFFFAOYSA-N 3-cyano-2-methylbenzoic acid Chemical compound CC1=C(C#N)C=CC=C1C(O)=O QPEFUCOMFYTEKE-UHFFFAOYSA-N 0.000 description 1
- XMKZAIHFVHJGPV-UHFFFAOYSA-N 3-fluoro-2-methylbenzoic acid Chemical compound CC1=C(F)C=CC=C1C(O)=O XMKZAIHFVHJGPV-UHFFFAOYSA-N 0.000 description 1
- JJWOUNTXPOZVDP-UHFFFAOYSA-N 3-phenyl-3-pyridazin-4-ylpropanoyl azide Chemical compound C=1C=NN=CC=1C(CC(=O)N=[N+]=[N-])C1=CC=CC=C1 JJWOUNTXPOZVDP-UHFFFAOYSA-N 0.000 description 1
- IGCOUHSHBPYFSO-UHFFFAOYSA-N 4,4-difluoro-1-(2-methylpyrimidin-5-yl)cyclohexane-1-carbonitrile Chemical compound C1=NC(C)=NC=C1C1(C#N)CCC(F)(F)CC1 IGCOUHSHBPYFSO-UHFFFAOYSA-N 0.000 description 1
- DLKIKBCIOGMDQK-UHFFFAOYSA-N 4,4-difluoro-1-(4-methylimidazol-1-yl)cyclohexane-1-carboxamide Chemical compound C1=NC(C)=CN1C1(C(N)=O)CCC(F)(F)CC1 DLKIKBCIOGMDQK-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- MPZMVUQGXAOJIK-UHFFFAOYSA-N 4-bromopyridine;hydron;chloride Chemical compound Cl.BrC1=CC=NC=C1 MPZMVUQGXAOJIK-UHFFFAOYSA-N 0.000 description 1
- IVYMIRMKXZAHRV-UHFFFAOYSA-N 4-chlorophenylacetonitrile Chemical compound ClC1=CC=C(CC#N)C=C1 IVYMIRMKXZAHRV-UHFFFAOYSA-N 0.000 description 1
- XGAFCCUNHIMIRV-UHFFFAOYSA-N 4-chloropyridine;hydron;chloride Chemical compound Cl.ClC1=CC=NC=C1 XGAFCCUNHIMIRV-UHFFFAOYSA-N 0.000 description 1
- KEJMSTJTAWACNI-UHFFFAOYSA-N 4-cyano-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(C#N)C=C1F KEJMSTJTAWACNI-UHFFFAOYSA-N 0.000 description 1
- FGERXQWKKIVFQG-UHFFFAOYSA-N 5-bromo-2-chlorobenzoic acid Chemical compound OC(=O)C1=CC(Br)=CC=C1Cl FGERXQWKKIVFQG-UHFFFAOYSA-N 0.000 description 1
- ZEZKXPQIDURFKA-UHFFFAOYSA-N 5-bromo-2-iodopyrimidine Chemical compound BrC1=CN=C(I)N=C1 ZEZKXPQIDURFKA-UHFFFAOYSA-N 0.000 description 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
- XYLPLVUYPAPCML-UHFFFAOYSA-N 5-chloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(Cl)=C1 XYLPLVUYPAPCML-UHFFFAOYSA-N 0.000 description 1
- JVBLXLBINTYFPR-UHFFFAOYSA-N 5-fluoro-2-methylbenzoic acid Chemical compound CC1=CC=C(F)C=C1C(O)=O JVBLXLBINTYFPR-UHFFFAOYSA-N 0.000 description 1
- BXZSBDDOYIWMGC-UHFFFAOYSA-N 5-fluoropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(F)=C1 BXZSBDDOYIWMGC-UHFFFAOYSA-N 0.000 description 1
- JNYLMODTPLSLIF-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)N=C1 JNYLMODTPLSLIF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- FQEMQYHUDOOVBE-UHFFFAOYSA-N C(C)(=O)C1(C(OCC1)=O)Cl.C(C)OC(=O)C1(CC1)C(F)F Chemical compound C(C)(=O)C1(C(OCC1)=O)Cl.C(C)OC(=O)C1(CC1)C(F)F FQEMQYHUDOOVBE-UHFFFAOYSA-N 0.000 description 1
- ZLUGUXXWGHFBGA-UHFFFAOYSA-N C1=NC(C(F)(F)F)=CC=C1C(C#N)C1=CC=CC=C1 Chemical compound C1=NC(C(F)(F)F)=CC=C1C(C#N)C1=CC=CC=C1 ZLUGUXXWGHFBGA-UHFFFAOYSA-N 0.000 description 1
- JMOITGKZHOGRDV-UHFFFAOYSA-N C1=NC(C(F)(F)F)=NC=C1C1(C#N)CCOCC1 Chemical compound C1=NC(C(F)(F)F)=NC=C1C1(C#N)CCOCC1 JMOITGKZHOGRDV-UHFFFAOYSA-N 0.000 description 1
- KMVSTSFCCGXSBQ-UHFFFAOYSA-N C1=NC(C)=CC=C1C1(CN)CCC(F)(F)CC1 Chemical compound C1=NC(C)=CC=C1C1(CN)CCC(F)(F)CC1 KMVSTSFCCGXSBQ-UHFFFAOYSA-N 0.000 description 1
- XTTLZIAFAWLBRK-UHFFFAOYSA-N C1=NC(C)=CC=C1C1(CNC(=O)C=2C(=C(Cl)C=CC=2)Cl)CCC(F)(F)CC1 Chemical compound C1=NC(C)=CC=C1C1(CNC(=O)C=2C(=C(Cl)C=CC=2)Cl)CCC(F)(F)CC1 XTTLZIAFAWLBRK-UHFFFAOYSA-N 0.000 description 1
- IYDJUSLYMFMXJZ-UHFFFAOYSA-N C1=NC(C)=NC=C1C1(C#N)COCC1 Chemical compound C1=NC(C)=NC=C1C1(C#N)COCC1 IYDJUSLYMFMXJZ-UHFFFAOYSA-N 0.000 description 1
- UGBTZGCYDPDABL-NVMNQCDNSA-N C=1N=C(C)N=CC=1C1(C(=N\O)/C)CCC(F)(F)CC1 Chemical compound C=1N=C(C)N=CC=1C1(C(=N\O)/C)CCC(F)(F)CC1 UGBTZGCYDPDABL-NVMNQCDNSA-N 0.000 description 1
- AJZBHYAZTVXCME-UHFFFAOYSA-N COC(=O)C1=C(O)CCC(C1)(C#N)c1cncnc1 Chemical compound COC(=O)C1=C(O)CCC(C1)(C#N)c1cncnc1 AJZBHYAZTVXCME-UHFFFAOYSA-N 0.000 description 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 1
- OPHNOSLOPXXLBN-UHFFFAOYSA-N COC1=CC=CC(C(=O)NCC2(CCC(F)(F)CC2)C=2C=NC(=CC=2)C(F)(F)F)=C1Cl Chemical compound COC1=CC=CC(C(=O)NCC2(CCC(F)(F)CC2)C=2C=NC(=CC=2)C(F)(F)F)=C1Cl OPHNOSLOPXXLBN-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- UFASPEWKRRSEOY-UHFFFAOYSA-N FC1=CN=CC(C2(CCC(F)(F)CC2)C#N)=C1 Chemical compound FC1=CN=CC(C2(CCC(F)(F)CC2)C#N)=C1 UFASPEWKRRSEOY-UHFFFAOYSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000632319 Homo sapiens Septin-7 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229910013470 LiC1 Inorganic materials 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 101001098235 Mus musculus P2X purinoceptor 7 Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 229910017912 NH2OH Inorganic materials 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 101100109871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-8 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101800000616 P-beta Proteins 0.000 description 1
- 102400000817 P-beta Human genes 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- CVQUWLDCFXOXEN-UHFFFAOYSA-N Pyran-4-one Chemical compound O=C1C=COC=C1 CVQUWLDCFXOXEN-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229910018162 SeO2 Inorganic materials 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 102100027981 Septin-7 Human genes 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- DTAZZRGLQFRMKY-UHFFFAOYSA-N [3-(2-methylpyrimidin-5-yl)oxolan-3-yl]methanamine Chemical compound C1=NC(C)=NC=C1C1(CN)COCC1 DTAZZRGLQFRMKY-UHFFFAOYSA-N 0.000 description 1
- FBAZQNQNPCXHEZ-UHFFFAOYSA-N [4,4-difluoro-1-(5-fluoropyridin-3-yl)cyclohexyl]methanamine Chemical compound C=1N=CC(F)=CC=1C1(CN)CCC(F)(F)CC1 FBAZQNQNPCXHEZ-UHFFFAOYSA-N 0.000 description 1
- QRCVHNPXCMDFNV-UHFFFAOYSA-N [4,4-difluoro-1-(6-fluoropyridin-3-yl)cyclohexyl]methanamine Chemical compound C=1C=C(F)N=CC=1C1(CN)CCC(F)(F)CC1 QRCVHNPXCMDFNV-UHFFFAOYSA-N 0.000 description 1
- YWLQOJHSDYQBRR-UHFFFAOYSA-N [4,4-difluoro-1-[2-(trifluoromethyl)pyrimidin-5-yl]cyclohexyl]methanamine Chemical compound C=1N=C(C(F)(F)F)N=CC=1C1(CN)CCC(F)(F)CC1 YWLQOJHSDYQBRR-UHFFFAOYSA-N 0.000 description 1
- ZQEQNZBKNTXAHE-UHFFFAOYSA-N [4-[2-(trifluoromethyl)pyrimidin-5-yl]oxan-4-yl]methanamine Chemical compound C=1N=C(C(F)(F)F)N=CC=1C1(CN)CCOCC1 ZQEQNZBKNTXAHE-UHFFFAOYSA-N 0.000 description 1
- JGLUGLOJKIXUNJ-UHFFFAOYSA-N [4-[4-(trifluoromethyl)phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(C(F)(F)F)C=CC=1C1(CN)CCOCC1 JGLUGLOJKIXUNJ-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000025748 atypical depressive disease Diseases 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 1
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 1
- KWDMKGGYWWDZOW-GXDHUFHOSA-N ethyl (e)-3-phenyl-3-pyridazin-4-ylprop-2-enoate Chemical compound C=1C=NN=CC=1C(=C/C(=O)OCC)/C1=CC=CC=C1 KWDMKGGYWWDZOW-GXDHUFHOSA-N 0.000 description 1
- IJTDZYNZXZMHSE-UHFFFAOYSA-N ethyl 1-(difluoromethyl)cyclopropane-1-carboxylate Chemical compound CCOC(=O)C1(C(F)F)CC1 IJTDZYNZXZMHSE-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- SDAXRHHPNYTELL-UHFFFAOYSA-N heptanenitrile Chemical compound CCCCCCC#N SDAXRHHPNYTELL-UHFFFAOYSA-N 0.000 description 1
- TXGJTWACJNYNOJ-UHFFFAOYSA-N hexane-2,4-diol Chemical compound CCC(O)CC(C)O TXGJTWACJNYNOJ-UHFFFAOYSA-N 0.000 description 1
- 102000053195 human P2RX7 Human genes 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- DGOYLVBDCVINQZ-UHFFFAOYSA-N oxane-4-carboxamide Chemical compound NC(=O)C1CCOCC1 DGOYLVBDCVINQZ-UHFFFAOYSA-N 0.000 description 1
- UHBGYFCCKRAEHA-UHFFFAOYSA-N p-methylbenzamide Natural products CC1=CC=C(C(N)=O)C=C1 UHBGYFCCKRAEHA-UHFFFAOYSA-N 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- JIWDQJYCCQFDAF-UHFFFAOYSA-N potassium;2-methylpropan-2-olate;oxolane Chemical compound [K+].CC(C)(C)[O-].C1CCOC1 JIWDQJYCCQFDAF-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ZBGMIPHSJPRFNN-UHFFFAOYSA-N propanoyl azide Chemical compound CCC(=O)N=[N+]=[N-] ZBGMIPHSJPRFNN-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000001696 purinergic effect Effects 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000003572 second messenger assay Methods 0.000 description 1
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000000526 short-path distillation Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YZUAOVCUGSBIPP-UHFFFAOYSA-N tert-butyl N-[1-([1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl]carbamate Chemical compound C1=CC=CN2C(C(NC(=O)OC(C)(C)C)C)=NN=C21 YZUAOVCUGSBIPP-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000008448 thought Effects 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/73—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713113P | 2012-10-12 | 2012-10-12 | |
| US61/713,113 | 2012-10-12 | ||
| PCT/EP2013/071247 WO2014057078A1 (en) | 2012-10-12 | 2013-10-11 | Benzamides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2887096A1 CA2887096A1 (en) | 2014-04-17 |
| CA2887096C true CA2887096C (en) | 2021-02-16 |
Family
ID=49551580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2887096A Active CA2887096C (en) | 2012-10-12 | 2013-10-11 | Benzamides inhibitors of the p2x7 receptor |
Country Status (42)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI598325B (zh) * | 2012-10-12 | 2017-09-11 | H 朗德貝克公司 | 苯甲醯胺類 |
| TW201427947A (zh) | 2012-10-12 | 2014-07-16 | Lundbeck & Co As H | 環狀胺 |
| PL2931717T3 (pl) | 2012-12-12 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Pochodne indolokarboksyamidu jako antagoniści receptora p2x7 |
| AR094053A1 (es) | 2012-12-18 | 2015-07-08 | Actelion Pharmaceuticals Ltd | Derivados de indol carboxamida como antagonistas del receptor p2x₇ |
| EP2956457B1 (en) | 2013-01-22 | 2016-11-23 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| ES2616114T3 (es) | 2013-01-22 | 2017-06-09 | Actelion Pharmaceuticals Ltd. | Derivados de amida heterocíclica como antagonistas del receptor P2X7 |
| CN105503787A (zh) * | 2015-12-31 | 2016-04-20 | 阜阳欣奕华材料科技有限公司 | 一种索非布韦中间体的纯化方法 |
| CN106366056B (zh) * | 2016-08-26 | 2018-12-11 | 常州市阳光药业有限公司 | 3-氨甲基四氢呋喃的制备方法 |
| SI3609868T1 (sl) * | 2017-03-13 | 2024-03-29 | Raqualia Pharma Inc. | Derivati tetrahidrokinolina kot antagonisti receptorja P2X7 |
| WO2019226213A2 (en) | 2018-03-08 | 2019-11-28 | Incyte Corporation | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| CN117088877A (zh) * | 2020-10-28 | 2023-11-21 | 杭州阿诺生物医药科技有限公司 | 一种高活性Wnt通路抑制剂化合物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445707A1 (de) | 1962-05-05 | 1969-03-13 | Hoechst Ag | Piperidinverbindungen und Verfahren zu ihrer Herstellung |
| US3435038A (en) * | 1965-06-01 | 1969-03-25 | Sandoz Ag | 5,6,7,9,10,14b-hexahydroisoquinolo (2,1-d) benzo (1,4) diazepines |
| US6303637B1 (en) * | 1998-10-30 | 2001-10-16 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
| US6194458B1 (en) * | 1998-10-30 | 2001-02-27 | Merck & Co., Inc. | Benzamide potassium channel inhibitors |
| US6632836B1 (en) * | 1998-10-30 | 2003-10-14 | Merck & Co., Inc. | Carbocyclic potassium channel inhibitors |
| SE0003476D0 (sv) * | 2000-09-28 | 2000-09-28 | Astrazeneca Ab | Compounds |
| TW200300083A (en) | 2001-11-12 | 2003-05-16 | Pfizer Prod Inc | Benzamide, heteroarylamide and reverse amides |
| PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| PA8591801A1 (es) * | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
| ATE355273T1 (de) * | 2003-05-12 | 2006-03-15 | Pfizer Prod Inc | Benzamidinhibitoren des p2x7-rezeptors |
| AU2004263179B8 (en) | 2003-08-08 | 2011-07-14 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| TWI368482B (en) | 2003-12-19 | 2012-07-21 | Bayer Sas | New 2-pyridinylethylbenzamide derivatives |
| EP1729772B8 (en) | 2004-03-24 | 2017-04-19 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine glycine transporter inhibitors |
| JP2008504363A (ja) * | 2004-06-29 | 2008-02-14 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | P2x7受容体のベンズアミド阻害剤を利用する併用療法 |
| ATE476431T1 (de) * | 2004-12-21 | 2010-08-15 | Merck Sharp & Dohme | Piperidin- und azetidinderivate als glyt1- inhibitoren |
| WO2006080884A1 (en) * | 2005-01-27 | 2006-08-03 | Astrazeneca Ab | Novel biaromatic compounds, inhibitors of the p2x7-receptor |
| CA2611376C (en) * | 2005-06-13 | 2013-09-10 | Merck Sharp & Dohme Limited | Therapeutic agents |
| CA2625039A1 (en) | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors |
| JP2009057282A (ja) | 2005-12-19 | 2009-03-19 | Astellas Pharma Inc | カルボン酸誘導体又はその塩 |
| TWI435863B (zh) * | 2006-03-20 | 2014-05-01 | Nihon Nohyaku Co Ltd | N-2-(雜)芳基乙基甲醯胺衍生物及含該衍生物之蟲害防治劑 |
| RU2010103102A (ru) * | 2007-07-02 | 2011-08-10 | Зингента Партисипейшнс Аг (Ch) | Новые микробиоциды |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| JP5369173B2 (ja) * | 2008-04-22 | 2013-12-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キノリン若しくはイソキノリン置換p2x7アンタゴニスト |
| ES2345527B1 (es) * | 2008-10-08 | 2011-09-08 | Hospital Clinic I Provincial De Barcelona | Sustancias bloqueadoras de los canales kv 1.3 para el tratamiento de enfermedades asociadas a hiperplasia de la intima. |
| CA2804716A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| CA2828060C (en) * | 2011-03-02 | 2018-11-06 | The University Of Tokyo | Endoparasite control agent |
| RU2608217C2 (ru) * | 2011-11-02 | 2017-01-17 | Байер Интеллектуэль Проперти Гмбх | Соединения с нематоцидной активностью |
| PL2782565T3 (pl) * | 2011-11-25 | 2020-08-24 | Bayer Intellectual Property Gmbh | Zastosowanie arylo- i heteroarylokarboksyamidów jako środki endopasożytobójcze |
| TW201427947A (zh) * | 2012-10-12 | 2014-07-16 | Lundbeck & Co As H | 環狀胺 |
| TWI598325B (zh) | 2012-10-12 | 2017-09-11 | H 朗德貝克公司 | 苯甲醯胺類 |
-
2013
- 2013-10-09 TW TW102136498A patent/TWI598325B/zh active
- 2013-10-10 AR ARP130103681A patent/AR092973A1/es unknown
- 2013-10-10 US US14/050,431 patent/US9102591B2/en active Active
- 2013-10-11 ME MEP-2018-51A patent/ME02982B/me unknown
- 2013-10-11 GE GEAP201313785A patent/GEP201706621B/en unknown
- 2013-10-11 EA EA201590562A patent/EA026396B1/ru not_active IP Right Cessation
- 2013-10-11 ES ES13786633.1T patent/ES2662523T3/es active Active
- 2013-10-11 RU RU2015113320A patent/RU2015113320A/ru not_active Application Discontinuation
- 2013-10-11 CA CA2887096A patent/CA2887096C/en active Active
- 2013-10-11 CN CN201380052671.6A patent/CN104884445B/zh not_active Expired - Fee Related
- 2013-10-11 NZ NZ630830A patent/NZ630830A/en not_active IP Right Cessation
- 2013-10-11 SM SM20180136T patent/SMT201800136T1/it unknown
- 2013-10-11 AU AU2013328584A patent/AU2013328584B2/en not_active Ceased
- 2013-10-11 TR TR2018/02992T patent/TR201802992T4/tr unknown
- 2013-10-11 PT PT137866331T patent/PT2906546T/pt unknown
- 2013-10-11 BR BR112015008117A patent/BR112015008117A2/pt not_active IP Right Cessation
- 2013-10-11 LT LTEP13786633.1T patent/LT2906546T/lt unknown
- 2013-10-11 AP AP2015008406A patent/AP2015008406A0/xx unknown
- 2013-10-11 HR HRP20180272TT patent/HRP20180272T1/hr unknown
- 2013-10-11 SG SG11201502680QA patent/SG11201502680QA/en unknown
- 2013-10-11 RS RS20180243A patent/RS56925B1/sr unknown
- 2013-10-11 HU HUE13786633A patent/HUE038223T2/hu unknown
- 2013-10-11 EP EP13786633.1A patent/EP2906546B1/en active Active
- 2013-10-11 KR KR1020157009187A patent/KR20150067188A/ko not_active Withdrawn
- 2013-10-11 WO PCT/EP2013/071247 patent/WO2014057078A1/en not_active Ceased
- 2013-10-11 SI SI201330967T patent/SI2906546T1/en unknown
- 2013-10-11 PL PL13786633T patent/PL2906546T3/pl unknown
- 2013-10-11 DK DK13786633.1T patent/DK2906546T3/en active
- 2013-10-11 MX MX2015004412A patent/MX369717B/es active IP Right Grant
- 2013-10-11 JP JP2015536142A patent/JP6515409B2/ja not_active Expired - Fee Related
- 2013-10-11 PE PE2015000466A patent/PE20150709A1/es not_active Application Discontinuation
-
2014
- 2014-09-18 NO NO14185271A patent/NO2851818T3/no unknown
-
2015
- 2015-03-23 IL IL237914A patent/IL237914A0/en unknown
- 2015-03-23 TN TNP2015000107A patent/TN2015000107A1/fr unknown
- 2015-03-26 DO DO2015000076A patent/DOP2015000076A/es unknown
- 2015-03-26 CR CR20150171A patent/CR20150171A/es unknown
- 2015-04-06 PH PH12015500746A patent/PH12015500746A1/en unknown
- 2015-04-08 NI NI201500050A patent/NI201500050A/es unknown
- 2015-04-09 CL CL2015000902A patent/CL2015000902A1/es unknown
- 2015-04-09 EC ECIEPI201513883A patent/ECSP15013883A/es unknown
- 2015-04-10 MA MA37990A patent/MA37990B1/fr unknown
- 2015-06-19 US US14/744,103 patent/US9649308B2/en not_active Expired - Fee Related
-
2017
- 2017-04-05 US US15/479,972 patent/US10238654B2/en active Active
-
2018
- 2018-03-09 CY CY20181100291T patent/CY1120008T1/el unknown
- 2018-12-20 JP JP2018238486A patent/JP6632701B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-25 US US16/283,929 patent/US20200054630A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2887096C (en) | Benzamides inhibitors of the p2x7 receptor | |
| US10124010B2 (en) | Cyclic amines | |
| JP7114591B2 (ja) | Gsk-3阻害剤 | |
| OA17264A (en) | Benzamides. | |
| HK1214242B (en) | Benzamides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180913 |